Preferred Label : Osilodrostat;
NCIt synonyms : (R)-4-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile;
NCIt definition : An orally bioavailable inhibitor of both steroid 11beta-hydroxylase (cytochrome P450
(CYP) 11B1) and aldosterone synthase (CYP11B2; steroid 18-hydroxylase), with potential
anti-adrenal activity and ability to treat Cushing disease (CD). Upon administration,
osilodrostat binds to and inhibits the activity of CYP11B1, the enzyme that catalyzes
the final step of cortisol synthesis from the precursor 11-deoxycortisol, and CYP11B2,
the enzyme that catalyzes aldosterone synthesis from corticosterone and 11-deoxycorticosterone
in the adrenal gland. The inhibition of CYP11B1 prevents the production of excess
cortisol, thereby decreasing and normalizing the levels of cortisol. CD is most often
caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor.;
UNII : 5YL4IQ1078;
InChIKey : USUZGMWDZDXMDG-CYBMUJFWSA-N;
CAS number : 928134-65-0;
Molecule name : LCI-699; LCI 699;
Origin ID : C131535;
UMLS CUI : C4330903;
CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
https://www.has-sante.fr/jcms/p_3265513/fr/isturisa-osilodrostat
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Osilodrostat
Osilodrostat
osilodrostat
administration, oral
adult
cushing syndrome
Endogenous Cushing Syndrome
evaluation of the transparency committee
imidazoles
pyridines
---
